Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of “Hold” by Analysts

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has been assigned a consensus recommendation of “Hold” from the six analysts that are currently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $9.60.

Several research analysts recently weighed in on the company. Royal Bank of Canada lowered Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their target price for the stock from $11.00 to $2.00 in a research report on Tuesday, November 5th. HC Wainwright cut Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, November 6th. Brookline Capital Management restated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday, November 5th. Finally, TD Cowen reduced their target price on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, October 21st.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC bought a new stake in Verrica Pharmaceuticals in the second quarter valued at $50,000. Key Financial Inc bought a new position in Verrica Pharmaceuticals in the 2nd quarter worth about $69,000. Rhumbline Advisers increased its stake in shares of Verrica Pharmaceuticals by 20.4% in the second quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock valued at $194,000 after purchasing an additional 4,514 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $332,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Verrica Pharmaceuticals by 8.1% during the second quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company’s stock worth $428,000 after buying an additional 4,393 shares during the period. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Price Performance

Shares of NASDAQ:VRCA opened at $0.86 on Friday. The business has a fifty day simple moving average of $1.47 and a 200-day simple moving average of $4.90. Verrica Pharmaceuticals has a 52 week low of $0.70 and a 52 week high of $11.41. The company has a market cap of $39.37 million, a P/E ratio of -0.47 and a beta of 1.45. The company has a quick ratio of 1.22, a current ratio of 1.34 and a debt-to-equity ratio of 29.58.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The company had revenue of ($1.78) million for the quarter, compared to analyst estimates of $7.53 million. Equities research analysts forecast that Verrica Pharmaceuticals will post -1.42 EPS for the current year.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.